

Molecular mechanism of DNA topoisomerase I-dependent

rDNA silencing: Sir2p recruitment at ribosomal genes.

AUTHORS

Anna D'Alfonso ⁽¹⁾, Francesca Di Felice ⁽¹⁾, Valentina Carlini ⁽¹⁾, Christine M Wright ⁽²⁾,
Marla I Hertz ⁽²⁾, Mary-Ann Bjornsti ^{(2)*} and Giorgio Camilloni, ^{(1, 3)*}

AFFILIATIONS

(1) Dipartimento di Biologia e Biotecnologie, Università di Roma Sapienza, Roma,
00185, Italy

(2) Department of Pharmacology and Toxicology, University of Birmingham at Alabama,
Birmingham AL, 35294, USA

(3) Istituto Pasteur, Fondazione Cenci Bolognetti, Università di Roma Sapienza, Roma,
00185, Italy

Anna D'Alfonso, dalfonsoanna@yahoo.it
Francesca Di Felice, francesca.difelice@uniroma1.it
Valentina Carlini, vale611@hotmail.it
Christine M Wright, cwright7@uab.edu
Marla I Hertz, marla.hertz@gmail.com
Mary-Ann Bjornsti, bjornsti@uab.edu
Giorgio Camilloni, giorgio.camilloni@umiroma1.it

* To whom correspondence should be addressed

Mary-Ann Bjornsti Tel: +1 2059344579; Email: bjornsti@uab.edu

Giorgio Camilloni. Tel: +39 0649912808. Fax: +39 0649912500. Email:
giorgio.camilloni@umiroma1.it

ABSTRACT

Saccharomyces cerevisiae *sir2Δ* or *top1Δ* mutants exhibit similar phenotypes involving ribosomal DNA, including; i) loss of transcriptional silencing, resulting in non-coding (nc)RNA hyper-production from cryptic RNA Polymerase II promoters; ii) alterations in recombination; and iii) a general increase in histone acetylation. Given the distinct enzymatic activities of Sir2 and Top1 proteins, a histone deacetylase and a DNA topoisomerase, respectively, we investigated whether genetic and/or physical interactions between the two proteins could explain the shared rDNA phenotypes. We employed an approach of complementing *top1Δ* cells with yeast, human, truncated and chimeric yeast/human *TOP1* constructs, and assessing the extent of ncRNA silencing and histone H4K16 deacetylation. Our findings demonstrate that residues 115-125 within the yeast Top1p N-terminal domain are required for complementation of the *top1Δ* rDNA phenotypes. In chromatin immunoprecipitation (ChIP) and co-immunoprecipitation experiments, we further demonstrate the physical interaction between Top1p and Sir2p. Our genetic and biochemical studies support a model whereby Top1p recruits Sir2p to the rDNA, and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA, independent of its known catalytic activity.

Keywords: DNA topoisomerase I; Sir2p; Transcriptional silencing; histone acetylation; rDNA.

INTRODUCTION

In the budding yeast *Saccharomyces cerevisiae*, the ribosomal RNA genes (rDNA) are arrayed in tandem repeats of 150-200 units on chromosome XII (1). Each repeated unit is interrupted by an Intergenic Spacer Region (IGS), which contains: i) a replication origin (ARS, for autonomous replicating sequence); ii) a promoter of the 35S RNA gene that is transcribed by RNA polymerase I (Pol I), iii) the 5S RNA gene transcribed by RNA polymerase III (Pol III); and iv) two cryptic non-coding RNA promoters (E-pro and C-pro), which are transcribed at low levels by RNA polymerase II (Pol II). In addition, each unit includes a replication fork barrier (RFB). Binding of the Fob1 protein to RFB sites selectively stalls the movement of replication forks in only direction (2). This asymmetric stalling of only one of the bi-directional replication forks at Fob1p-bound RFB sites avoids the adverse effects that would otherwise result from head-on collisions between the advancing replication machinery and transcription bubbles. At RFBs, recombination events also occur that maintain the homogeneity of the rDNA units. Dysregulation of these events leads to change in unit copy number and/or the formation of extrachromosomal rDNA circles (ERCs) (3).

The locus of tandem rDNA repeats is a highly active region of the genome at which concurrent DNA replication, transcription and recombination occurs (4). Consequently, strict control of polynucleotide polymerization and recombination are necessary to maintain rDNA stability. In this regard, the epigenetic state of rDNA chromatin, in particular the acetylation of histone H4 at residue Lys16 (H4K16) (5), has been demonstrated to be crucial for the coordination of these enzymatic functions.

Sir2p is one of four Silent Information Regulator (SIR) genes in yeast that function in transcription silencing. However, Sir2p uniquely possesses NAD⁺-dependent

1
2
3
4 histone deacetylase activity and is the only *SIR* gene product to function in the
5
6 nucleolus. Yeast strains deleted for the *SIR2* gene (*sir2Δ*), exhibit several phenotypes
7
8 involving rDNA gene dysregulation, such as the loss of transcriptional silencing (6, 7),
9
10 which results in ncRNA hyper-production from the cryptic Pol II promoters, E-pro and C-
11
12 pro (8), and alterations in recombination (9), as evidenced by changes in rDNA unit
13
14 copy number or elevated production of ERCs (10). Furthermore, *sir2Δ* mutants exhibit a
15
16 general increase in histone acetylation of rDNA chromatin, particularly at H4K12, H4K16
17
18 and H3K9 residues (11). Indeed, the rDNA defects observed in *sir2Δ* mutants are
19
20 consistent with the loss of Sir2p histone deacetylase activity (12; 13; 14; 15).
21
22
23

24
25
26 Deletion of the *TOP1* gene, which encodes DNA topoisomerase 1 (Top1p), also
27
28 impacts rDNA, and the features of these *top1Δ* phenotypes almost completely overlap
29
30 those observed in *sir2Δ* mutants. Notably, rDNA repeat hyper-recombination, loss of
31
32 rDNA transcriptional silencing and the hyperacetylation of histone residues have all
33
34 been reported in *top1Δ* mutants (16; 17; 18; 19; 20). The gene products of *SIR2* and
35
36 *TOP1* represent distinct enzymatic functions; the NAD⁺-dependent deacetylase activity
37
38 of Sir2p and the alterations in the linkage or intertwining of DNA strands catalyzed by
39
40 DNA topoisomerase I (Top1p), with no obvious homology shared between the two
41
42 enzymes. Thus, it is not clear why the altered rDNA phenotypes exhibited by *top1Δ* cells
43
44 are so similar to those observed in *sir2Δ* mutants.
45
46
47
48
49

50
51 In this work, we sought to determine how the loss of Top1p (in *top1Δ* strains)
52
53 causes alterations in phenotypes involving rDNA. In particular, we focused our attention
54
55 on structural features of Top1p that impact epigenetic aspects of transcriptional
56
57 silencing of ncRNA from cryptic E-pro and C-pro promoters and acetylation of histone
58
59 H4K16 (21; 5), using a strategy of complementing *top1Δ* strains with a panel of *TOP1*
60
61
62
63
64
65

variant genes, including a series of human/yeast N-terminal *top1* chimeras (22). Our results indicate a physical interaction of Top1p with Sir2p, and suggest that select residues in the N-terminal domain of Top1p functions in the recruitment of Sir2p to the rDNA. This property of DNA topoisomerase I was independent of enzyme catalysis and illustrates a structural role for Top1p in the epigenetic regulation of rDNA.

RESULTS

Top1p functions in maintaining the extent of H4K16 acetylation and ncRNA silencing at the rDNA locus.

The loss of transcriptional silencing of rDNA repeats, and the increase in histone acetylation at the same locus, characterize both *sir2Δ* and *top1Δ* mutants in *S. cerevisiae* (6; 7). The histone H4K16 residue is the main target of the Sir2p NAD⁺-dependent deacetylase. In *sir2Δ* mutants, hyperacetylation of this residue has been demonstrated to induce a loss of transcriptional silencing, and leads to genome instability at rDNA (5). While these molecular features are consistent with the loss of the deacetylating activity of Sir2p, the underlying mechanisms involving Top1p in these phenotypes are not obvious. To elucidate the role of Top1p in regulating transcriptional silencing and histone acetylation at rDNA, we first assessed the extent of H4K16 acetylation and quantified ncRNA production in a *top1Δ* strain, which lacks Top1p.

The relative positions of the 35S gene and the functional elements of the intergenic spacer region (IGS) of the 9.1 Kb rDNA unit are diagrammed in Fig. 1. Five distinct DNA tracts in the IGS of the rDNA, encompassing the RFB, the cryptic E-pro promoter, the 5S promoter, an ARS, and the cryptic C-pro promoter (referred to as 1-5, respectively) were analyzed by chromatin immunoprecipitation (ChIP) with an anti-

1
2
3
4 H4K16ac antibody (Fig. 2A), in order to measure the extent of histone H4K16
5
6 acetylation. Relative to isogenic wild-type *TOP1* cells, *top1Δ* cells exhibit increased
7
8 levels of H4K16ac throughout the IGS sequences analyzed (see dotted line in Fig. 2A).
9
10 These results are consistent with those previously reported, which indicate an increase
11
12 in histone acetylation at rDNA in a *top1Δ* strain (19).
13
14

15
16 Previous observations demonstrate that rDNA histone acetylation levels correlate
17
18 with increased ncRNA production by RNA polymerase II transcription from the normally
19
20 cryptic E- and C- pro promoters (8; 5). To further characterize the functional
21
22 involvement of Top1p in ncRNA silencing, we measured the three ncRNAs from the IGS
23
24 (detailed in Fig. 1). Total RNA from isogenic *top1Δ* or wild-type *TOP1* strains were
25
26 subjected to semi-quantitative RT-PCR, normalized to *UBC6* mRNA expression (23),
27
28 and reported in the histogram of Fig. 2B. A significant ($p<0.05$) increase in the
29
30 production of the ncRNAs IGS1F and IGS1R from the E-pro promoter was evident in
31
32 *top1Δ* compared to wild-type cells (dotted line in Fig. 2B). However, in contrast, no
33
34 significant differences in IGS2 ncRNA levels were detected between wild-type and
35
36 *top1Δ* cells. Taken together, the data reported in Fig. 2 indicate that H4K16 acetylation
37
38 within the IGS of rDNA and ncRNA production from E-pro are, in part, regulated by
39
40 Top1p.
41
42
43
44
45
46
47
48
49

50 **Top1Y727Fp restores wild-type levels of H4K16 acetylation at the rDNA locus.**

51
52 Given the different enzymatic activities carried out by Sir2p and Top1p (histone
53
54 deacetylation versus nicking-religation activity on DNA), the remarkable similarity
55
56 among reported phenotypes is not easily explained. In order to shed light on these
57
58
59
60
61
62
63
64
65

1
2
3
4 overlapping phenotypes we first asked: is Top1p catalytic activity required to suppress
5
6 these rDNA phenotypes?
7
8

9 The active site tyrosine of Top1 (Tyr727) acts as a nucleophile to cleave one
10 strand of duplex DNA, and in a transesterification reaction, becomes covalently
11 attached to the 3' phosphoryl end of the nicked DNA strand. Substitution of Phe for
12 Tyr727 (in Top1Y727Fp) results in a catalytically inactive protein that is, nevertheless,
13
14 still able to bind duplex DNA (24; 25; 26). In order to evaluate the requirement for Top1p
15 catalysis on histone acetylation and ncRNA production, we transformed *top1Δ* cells with
16 a plasmid that constitutively expresses the *top1Y727F* allele from the *TOP1* gene
17 promoter (YCp*top1Y727F*). A similar plasmid expressing wild-type *TOP1* served as
18 control (YCp*TOP1*). The absence of Top1p catalytic activity in extracts of
19
20 YCp*top1Y727F* transformed cells was confirmed in a plasmid DNA relaxation assay
21 using negatively supercoiled plasmid DNA (see Fig. 1S).
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 The camptothecin (CPT) class of chemotherapeutics specifically targets Top1p,
37 by reversibly stabilizing the covalent enzyme-DNA intermediate formed during the
38 Top1p catalytic cycle (27; 28; 29). Thus, CPT treatment increases the stability of
39 covalent Top1p-DNA complexes in cells expressing wild-type Top1p, but has no impact
40 on cells expressing the catalytically inactive Top1Y727Fp (18). As shown in
41 Supplemental Fig. 1S, a strong Top1p cleavage site induced by CPT treatment (30) of
42 cells expressing Top1p was not evident in cells expressing the catalytically inactive, and
43 therefore CPT resistant, Top1Y727Fp.
44
45
46
47
48
49
50
51
52
53
54

55 To determine if Top1p catalytic activity was also required to suppress H4K16
56 acetylation to the levels observed in wild-type cells, *top1Δ* cells transformed with
57 plasmids YCp*TOP1* or YCp*top1Y727F* were grown in selective media. Wild-type *TOP1*
58
59
60
61
62
63
64
65

1
2
3
4 and *top1Δ* strains transformed with the empty vector (YCp50) were also analyzed as
5
6 controls. ChIP analyses were then performed as in Fig. 2A. Fig. 3A depicts the levels of
7
8 H4K16 acetylation detected in the 5 specified regions described in Fig.1, relative to that
9
10 observed in wild-type *TOP1* cells (dotted line). In contrast to the decrease in H4K16
11
12 acetylation detected in the absence of Top1p, H4K16 acetylation was restored to wild-
13
14 type levels by expression of Top1Y727Fp, across the IGS regions analyzed. Thus, it
15
16 appears that Top1p plays a structural, rather than a catalytic role in the maintenance of
17
18 histone H4K16 acetylation of the IGS of rDNA.
19
20
21
22
23
24

25 26 ***Top1Y727Fp* restores IGS1R ncRNA silencing.**

27
28 As transcription of ncRNAs from E-pro versus C-pro was selectively de-repressed in
29
30 *top1Δ* cells (20), we next asked if the extent of IGS1R silencing was also restored by
31
32 Top1Y727F expression. As shown in Fig. 3B, the amount of IGS1R ncRNA expressed
33
34 (relative to *UBC6* and normalized to wild-type *TOP1* cells) was equivalent in *top1Δ*
35
36 transformed with *TOP1* and *top1Y727F* expression vectors. Thus, as with H4K16
37
38 deacetylation, these results provide the unexpected observation that DNA
39
40 topoisomerase I catalytic activity is dispensable for ncRNA silencing.
41
42
43
44
45
46
47

48 **Human *TOP1* does not restore H4K16 acetylation or ncRNA silencing at the rDNA** 49 50 **locus.**

51
52 In eukaryotes, the monomeric nuclear DNA topoisomerase I is highly conserved in
53
54 terms of enzyme function and architecture. The human nuclear enzyme (hTop1) shares
55
56 42% identity with yeast Top1p (31) (protein alignment in Supplemental Fig. 5S). The
57
58 conserved core domains of yeast and human Top1p form a protein clamp that
59
60
61
62
63
64
65

1
2
3
4 completely circumscribes duplex DNA, while a coiled-coil linker domain of variable
5
6 length connects the core domain with the conserved C-terminal domain, which contains
7
8 the active site Tyr residue that cleaves the DNA (32; 33; 34; 35). These conserved core
9
10 and C-terminal domains are ~53 and 62% identical in amino acid sequence,
11
12
13 respectively. Thus, we asked if a structurally related DNA topoisomerase I, human Top1
14
15 (encoded by h*TOP1* cDNA), could also restore wild-type H4K16 acetylation and ncRNA
16
17 silencing yeast *top1Δ* cells.
18
19

20
21 To determine if h*TOP1* was able to complement the rDNA phenotypes attendant
22
23 with *TOP1* deletion, *GAL1*-promoted human *TOP1* cDNA constructs (YCp*GAL1*-
24
25 h*TOP1*) (34) or yeast *TOP1* vector (YCp*GAL1*-y*TOP1*) (34), were introduced into *top1Δ*
26
27 cells. The YCp*GAL1* empty vector, transformed into wild-type *TOP1* or *top1Δ* strains,
28
29 served as controls. Cells were grown in selective medium containing glucose as carbon
30
31 source, and *TOP1* expression was induced by shifting the cells into galactose
32
33 containing medium for 6 hours. The activity of the human and yeast enzymes was
34
35 assessed by the formation of CPT-induced covalent Top1p-DNA complexes in the rDNA
36
37 in yeast cells, and in plasmid DNA relaxation assays with crude cell extracts (see
38
39 Supplemental Fig. 2S). We then measured the extent of H4K16 acetylation by ChIP, as
40
41 described in Figs 2 and 3. As shown in Fig. 4A, the catalytically active human enzyme
42
43 could not suppress the levels of H4K16 acetylation to those observed in wild-type cells
44
45 (dotted line) or in *top1Δ* cells expressing plasmid-born yeast Top1p (Fig. 4A grey bars).
46
47 Human Top1p was also unable to restore silencing of transcription at the E-pro (Fig.
48
49 4B). RT-PCR quantitation of IGS1R ncRNA production, normalized to *UBC6* in wild-type
50
51 *TOP1* cells (dotted line), revealed that ncRNA transcription was unchanged in h*TOP1*
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 expressing cells when compared to *top1Δ* cells that contain empty vector, while
5
6 silencing was restored by the yeast *TOP1* gene.
7
8

9 Altogether, the data in Fig. 4 demonstrate that h*TOP1* failed to complement the
10
11 two molecular phenotypes of *top1Δ* cells (H4K16 acetylation and ncRNA de-
12
13 repression). These findings suggest that DNA topoisomerase I catalytic activity is
14
15 dispensable for ncRNA silencing and histone acetylation control at the rDNA locus, and
16
17 implicate differences in the protein sequence of these homologous enzymes in the
18
19 regulation of rDNA phenotypes.
20
21
22
23
24
25

26 **The N-terminal domain of DNA topoisomerase I impacts rDNA phenotypes.**

27
28 Our data suggest that distinct features or residues of Top1p, rather than enzyme
29
30 catalysis, are an important determinant of histone acetylation and silencing at the rDNA
31
32 locus, as the catalytically inactive yeast Top1Y727Fp complements the *top1Δ*-induced
33
34 rDNA phenotypes, while an active heterologous hTop1 enzyme does not. As shown in
35
36 Supplemental Fig. 5S, the N-terminal domains of yeast and human DNA topoisomerase
37
38 I are poorly conserved, both in terms of size and primary amino acid sequence. No
39
40 structural information is available for this domain, and it is dispensable for yeast and
41
42 human Top1p catalysis (36). Nevertheless, the N-terminal domain has been shown to
43
44 mediate Top1p-protein interactions (29). Thus we asked: is the yeast N-terminal domain
45
46 required for complementation of *top1Δ* phenotypes?
47
48
49
50
51

52
53 To address this question, we used a chimeric construct (*Sc210hTOP1*) that
54
55 encodes a fusion protein comprising amino acids 1 to 138 from *S. cerevisiae* Top1p and
56
57 residues 210 to 765 from the human enzyme, fused at a conserved junction between
58
59 the N-terminal and core domains of these enzymes. We recently reported that
60
61
62
63
64
65

1
2
3
4 swapping of the N-terminal domains of yeast and human Top1p did not impair the
5
6 specific catalytic activity or CPT sensitivity of the chimeric enzymes (22). A plasmid that
7
8 expresses the chimeric gene from the galactose-inducible *GAL1* promoter (YCp*GAL1-*
9
10 *Sc210hTOP1*) was used to transform *top1Δ* cells. Following induction with galactose,
11
12 the activity of the chimeric enzyme was assessed by the formation of CPT-induced
13
14 Top1p-DNA covalent complexes at the rDNA locus *in vivo* and in a plasmid DNA
15
16 relaxation assays using crude cell extracts (see Supplementary Fig. 3S). These cells
17
18 were then used in ChIP and RT-PCR analyses, as in Fig. 4. As shown in Fig. 5A,
19
20 acetylation of H4K16 residues within the IGS was restored to wild-type levels (dotted
21
22 line) in *top1Δ* cells expressing *Sc210hTOP1*. Similar results were obtained with *top1Δ*
23
24 cells transformed with YCp*GAL1-yTOP1*. The *Sc210hTOP1* chimera was also able to
25
26 restore rDNA silencing, as evidenced by the suppression of IGS1R ncRNA expression
27
28 (Fig.5B). These results demonstrate that yeast Top1p N-terminal residues 1-138, within
29
30 the context of the chimeric protein, provide the necessary protein sequences for
31
32 complementation of the rDNA phenotypes.
33
34
35
36
37
38
39
40
41
42

43 **DNA topoisomerase I contributes to Sir2p recruitment at the rDNA locus.**

44
45 As the N-terminal 138 residues of yeast Top1p suffice to enable human Top1p to
46
47 complement the rDNA defects in *top1Δ* cells (Fig. 5), we hypothesized that this domain
48
49 of Top1p acts in concert with other protein partner(s). Moreover, since *top1Δ* and *sir2Δ*
50
51 mutants exhibit a common loss of gene silencing and histone hyperacetylation at the
52
53 same locus, we posited that Top1p recruits Sir2p to the rDNA. To begin addressing this
54
55 model, ChIP experiments were performed with Sir2p antibodies to analyze regions
56
57 where Sir2p has previously been reported to bind (35S RNA promoter and RFB, regions
58
59
60
61
62
63
64
65

1 and 5 in Fig. 1) (37). As seen in Fig. 6, Sir2p was enriched at these regions of the rDNA repeats in wild-type TOP1 cells: a two-fold decrease in Sir2p bound to both the 35S RNA promoter and RFB was observed in *top1Δ* cells compared to an isogenic wild-type strain (black bars compared to the dotted line in Fig. 6). However, the effect of *top1Δ* on Sir2p binding to chromatin appears to be selective for the rDNA locus, as no decrease was evident at other Sir2p binding sites - telomeric sequences of chromosome IV and the HM-L locus (see Supplementary Fig. 4S). However, while Sir2p dependent-silencing at the HML alpha locus was maintained (not shown), the loss of telomeric region silencing in *top1Δ* cells has previously been reported (38). These distinct effects on Sir2p chromatin binding and transcriptional silencing indicate that a global loss of Sir2p activity is not induced by deletion of *TOP1*.

In Fig. 6A, wild-type levels of Sir2p in rDNA chromatin were restored in *top1Δ* cells that constitutively express plasmid-encoded yeast Top1p or Top1Y727Fp. Conversely, in *top1Δ* cells transformed with YCpGAL1-*hTOP1*, the amount of Sir2p remained the same as that observed in *top1Δ* cells (Fig. 6B). Thus, in agreement with silencing and acetylation phenotypes assessed in Figs. 2-5, the catalytically inactive Top1Y727Fp sufficed to restore Sir2p binding to rDNA, while the active human enzyme did not. Given that the Sc210hTop1 chimera also complemented *top1Δ*-induced defects in rDNA silencing and histone acetylation, we next investigated its ability to restore Sir2p binding at rDNA. Indeed, as shown in Fig. 6C, Sir2p levels were also restored in *top1Δ* cells expressing the yeast/human Top1p chimera. In this context, it is worth noting that it was not possible to investigate a possible role of the N-terminal polypeptide alone in recruiting Sir2p to the rDNA in the nucleolus, since it has been reported in human cells that the N-terminal domain (as a single polypeptide)

translocates from the nucleolus to the nucleoplasm (39), thus preventing any nucleolar - specific interactions.

A defined N-terminal region of yeast DNA topoisomerase I rescues ncRNA silencing.

To further characterize the specific N-terminal residues of yeast Top1 required to restore rDNA silencing and histone deacetylation, an additional series of previously described N-terminal yeast-human and human-yeast Top1p chimeras were analyzed: *ScΔ201hTOP1*; *Sc192hTOP1*; *h120ScTOP1*; *h138ScTOP1* (Fig. 7A) (22). YCpGAL1 plasmids containing the chimera gene constructs were transformed into *top1Δ* cells, and IGS1R ncRNA expression was evaluated by RT-PCR. As shown in Fig. 7B, expression of only one additional chimera, *ScΔ201hTOP1*, was able to restore ncRNA silencing. Thus, of the five chimeras examined, only those comprising yeast residues around amino acids 115-125 (in Sc210h and ScΔ201h, but not Sc192h) were active in complementing *top1Δ*-mediated rDNA dysregulation. As shown in Fig. 7A, the common element shared by wild-type yeast Top1p and the two chimeras capable of restoring ncRNA silencing is a continuous stretch of 6 glutamic acidic residues (highlighted yellow). In the case of ScΔ201h, the generation of this six residue acidic patch was a fortuitous consequence of a PCR-induced error in the generation of the chimera (22).

DNA topoisomerase I and Sir2p physically interact

Given the genetic interaction of yeast Top1p and Sir2p at the rDNA, we next asked if the observed phenotypes result from the physical interaction of these proteins. Protein extracts of isogenic wild-type *SIR2, top1Δ* or *sir2Δ, top1Δ* yeast cells expressing the

1
2
3
4 indicated yeast, human and chimeric Top1 proteins were subjected to
5
6 immunoprecipitation (IP) with a bead bound antibody that recognizes the N-terminal
7
8 FLAG epitope engineered into each *TOP1* construct. The bead bound proteins were
9
10 then immunoblotted with anti-FLAG or anti-Sir2 antibodies to assess co-
11
12 immunoprecipitation of Sir2p with Top1p. A yeast Topo70 construct was also included in
13
14 this analysis, as this ScTopo70p lacks the first 102 residues of yeast Top1p, yet still
15
16 contains the stretch of acidic residues found in the Sc Δ 201h and Sc210h chimeras (see
17
18 Fig. 7A). As seen in Fig. 8, Sir2p was detected following immunoprecipitation in the
19
20 yeast Top1p, ScTopo70p and chimera samples, with the strongest signal detected with
21
22 ScTopo70p expressing cells. Conversely, in the IP performed with extracts from cells
23
24 expressing hTop1p, Sir2p was not detected. Thus, Sir2p appeared to physically interact
25
26 with all proteins that contain yeast Top1p residues derived from sequences that span
27
28 the chimera junctions; yet, Sir2p did not interact with human Top1p. In this regard it is
29
30 worth noting that all of the Top1 proteins examined, with the exception of human Top1p,
31
32 contain longer stretches of acidic residues or more repeats of shorter patches of acidic
33
34 residues than those contained in the human enzyme (Fig. 7A). These elements may
35
36 suffice to mediate Sir2p binding to Top1p; however, the functional consequence of this
37
38 interaction on restoring ncRNA silencing is only evident with yeast Top1p, and the
39
40 Sc Δ 201h and Sc210h chimeras, which uniquely share a longer acidic patch (EEEEEE).
41
42
43
44
45
46
47
48
49
50
51
52

53 **DISCUSSION**

54
55 RNA polymerase II transcriptional silencing at the rDNA locus was first described in
56
57 1997 (6; 7), and different gene products have been reported to contribute to this
58
59 phenomenon (40). The *SIR2* gene product appears to comprise the main regulator of
60
61
62
63
64
65

1
2
3
4 silencing within this locus, and the histone deacetylase activity of Sir2p is crucial for this
5
6 function (41). The *TOP1* gene has also been implicated in rDNA silencing (6; 7).
7
8 However, the molecular basis of Top1p-mediated regulation of rDNA silencing was an
9
10 enigma, as the DNA nicking-religation activity of DNA topoisomerase I did not readily
11
12 suggest involvement in this process.
13
14

15
16 In order to understand the role of Top1p in RNA polymerase II silencing in rDNA
17
18 repeats, we first discerned that the enzymatic activity of Top1p was dispensable for
19
20 rDNA silencing. However, the physical presence of the Top1 protein was essential. In
21
22 particular, the *top1Δ* mutant defects in ncRNA production and histone acetylation were
23
24 complemented by plasmid encoded wild-type yeast *TOP1*, as well as the catalytically
25
26 inactive yeast *top1Y727F* mutant. The characteristic hyper-production of ncRNAs and
27
28 histone hyperacetylation at the IGS region, evident in *top1Δ* cells, were suppressed in
29
30 both cases, demonstrating that presence of Top1 protein alone sufficed to regulate
31
32 these two phenotypes. Since Top1Y727Fp binds DNA with the same affinity as wild-
33
34 type yeast Top1p (26; 42), these findings implicate specific protein interactions with
35
36 Top1p in Pol II silencing at the rDNA locus.
37
38
39
40
41

42
43 We further demonstrated that human Top1p, which shares a common reaction
44
45 mechanism, enzyme architecture, and 42% identity with the yeast enzyme (31), was
46
47 unable to restore rDNA silencing or suppress H4K16 acetylation in yeast *top1Δ* cells.
48
49 These findings suggest that specific sequences and/or structural elements unique to
50
51 yeast Top1p are required to restore the rDNA defects induced by deletion of the *TOP1*
52
53 gene. A structural role for human Top1 in Pol II transcriptional regulation has also been
54
55 reported: the catalytic activity of the human enzyme was dispensable for Top1 function
56
57 in the repression and activation of gene transcription in mammalian cells, yet the yeast
58
59
60
61
62
63
64
65

1
2
3
4 Top1 protein was not able to complement the loss of human Top1 (43; 44). Previous
5
6 reports further suggest that the DNA topoisomerase I N-terminal domain mediates
7
8 interactions with different protein partners (36; 45). Indeed, using a series of
9
10 yeast/human chimeras involving reciprocal swaps of the poorly conserved N-terminal
11
12 domains, our findings demonstrate a pivotal role for select yeast DNA topoisomerase I
13
14 N-terminal residues in maintaining the silencing and the epigenetic status of the rDNA.
15
16 Together these data illustrate that: i) Top1p contributes to Sir2p recruitment to rDNA
17
18 chromatin, but not other loci; ii) the recruitment of Sir2p to the rDNA does not depend on
19
20 Top1p catalytic activity; and iii) specific N-terminal residues of the yeast enzyme are
21
22 required for Sir2p recruitment.
23
24
25
26
27

28
29 The latter point in particular is intriguing and worthy of further consideration. With
30
31 Sc210hTop1, which comprises the first 138 residues of yeast Top1 fused to amino acid
32
33 residues 210-765 of human Top1, the catalytic activity and camptothecin sensitivity of
34
35 the fusion protein mirrored that of wild-type human Top1 (22). In the current studies,
36
37 Sc210hTop1 expressing cells behaved like wild-type yeast *TOP1*, strains,
38
39 demonstrating that the regulation of rDNA silencing and IGS histone H4K16 acetylation
40
41 is mostly due to the N-terminal sequences of yeast Top1, and correlates with the
42
43 physical recruitment of Sir2p to the rDNA. These results were not observed with human
44
45 Top1.
46
47
48
49

50
51 Nevertheless, our data further suggest that a physical interaction of Top1p with
52
53 Sir2p alone does not suffice to complement the rDNA defects of *top1Δ* cells. First, all of
54
55 the yeast/human Top1 chimeras examined (*Sc210hTOP1*; *ScΔ201hTOP1*;
56
57 *Sc192hTOP1*; *h120ScTOP1*; and *h138ScTOP1*), as well as ScTopo70 (which lacks the
58
59 first 102 residues of yeast Top1), were capable of associating with Sir2p in
60
61
62
63
64
65

immunoprecipitation experiments, albeit to varying levels (Fig. 8). Yet, only wild-type yeast Top1, ScTopo70, and two chimeras, Sc210hTop1p and ScΔ201hTop1p sufficed to restore wild-type levels of ncRNA silencing and IGS H4K16 acetylation. In this context, the deletion of 8 residues (EEEDKKAK) in ScΔ201hTop1p, an unintended error introduced in the generation of this chimera (22), nevertheless provided a critical insight into the functional elements within the N-terminal domain of yeast Top1p. As shown in Fig. 7A, the unique feature shared by the four constructs capable of restoring rDNA silencing and epigenetic regulation by Sir2p, is an R residue followed by a stretch of seven acidic residues EEEEEED and KKAK in yeast Top1p, ScTopo70p and Sc210hTop1p, or R followed by six acidic residues EEEEE and QKWK in ScΔ201hTop1. In contrast, Sc192hTop1p, which did not complement the rDNA of *top1Δ* cells, has R followed by a slightly shorter stretch of five acidic residues EEEEE and KKKPKK (see Fig. 7A). Unfortunately, the corresponding stretch of residues in human Top1p (EPDNKKKPKK) are not resolved in the crystal structures of human Topo70 (33, 35), and acidic/basic patches may not be expected to have well-defined secondary structure in solution. Nevertheless, these residues would be expected to reside on the surface of the protein. Moreover, if arrayed in an alpha-helix, the shorter stretch of acidic residues in Sc192hTop1p (REEEEEKKK) would produce a shift in registry of charge, such that one helical face would be net-positive. In contrast, with the longer acidic stretches in ScΔ201hTop1p (REEEEEEQK) or Top1p, ScTopo70p and Sc210hTop1p (REEEEEEDK), all helical faces would be net-negative. These differences could have profound effects on protein interactions with Top1p. An additional possibility is that the presence of a Pro within the adjoining human stretch of Lys residues in Sc192hTop1p (KKKPKK) may alter the structure of the yeast KKAK

residues to impair critical protein-protein interactions. Although these considerations await additional structural determinations of yeast and human Top1p N-terminal domains, our findings nevertheless lead to the following implications: a role for the N-terminal 138 residues of yeast Top1p in the physical binding of Sir2p; with residues in 115-125 of yeast Top1 required for the functional interactions necessary for complementation of *top1Δ*-induced rDNA defects. These data further establish the role of DNA topoisomerase I in the epigenetic regulation of rDNA, independent of enzyme catalysis.

MATERIALS AND METHODS

Yeast strains used in these studies were two pairs of isogenic strains: W303-1a (*MATa*, *ade2-1*, *ura3-1*, *his3-11,15*, *trp1-1*, *leu2-3,112*, *can1-100*), wild-type for TOP1 and AMR51 (W303-1a; *top1Δ::LEU2*); and EKY2 (*MATa*, *ura3-52*, *his3Δ200*, *leu2Δ1*, *trp1Δ63*, *top1Δ::HIS3*) (46) and MHY16 (EKY2, *sir2Δ::TRP1*). Yeast cells were grown and manipulated according to standard protocols (47). Culture media were YPD (complete media), and YNB without URA/ 2% glucose or YNB without URA/ 2% galactose (minimal media).

Plasmids that constitutively express yeast *TOP1* or *top1Y727F* from the yeast *TOP1* promoter (YCp*TOP1* and YCp*top1Y727F*, respectively) have been described (18). Galactose-inducible expression of wild-type yeast and human Top1p, yeast Topo70p, and a series of yeast/human and human/yeast N-terminal chimeric enzymes, was achieved with plasmids YCpGAL1yTOP1, YCpGAL1hTOP1, YCpGAL1yTopo70, YCpGAL1Sc192hTOP1, YCpGAL1ScΔ201hTOP1, YCpGAL1Sc210hTOP1, YCpGAL1h120ScTOP1, and YCpGAL1h138ScTOP1 as described (22). The Sc and h

designations indicate the order of yeast and human TOP1 sequences, respectively, while the number refers to the first amino acid residue encoded by the 3' chimera partner. For instance, in Sc210hTOP1, the junction between the N-terminal yeast Top1p sequences and the C-terminal human Top1p sequences begins with human residue 210. The construction of these chimeras was previously reported (22) and a diagram of the sequences flanking the chimeric junctions is provided in Fig. 7A. In all cases, the constructs were engineered with an N-terminal FLAG epitope tag. Oligonucleotide sequences are provided in Supplemental Table T1.

RT-PCR analysis

RNA from logarithmically growing cultures was isolated as previously described (48). 0.75 µg of DNase I treated RNA (30 min. at 37°C) were subjected to cDNA synthesis with Bioscript™ Reverse Transcriptase (Bioline reagents Ltd, United Kingdom) for 60 min at 42°C. *UBC6* and *IGS1R* ncRNA were reverse transcribed using an oligo dT primer. *IGS1F* ncRNA was reverse transcribed with an *IGS1Fr* specific primer (Supplemental Table T1). *IGS2* ncRNA was reverse transcribed using random hexamers. The reverse transcriptase reaction was stopped by heat inactivation of the enzyme at 85°C for 5 min. The resulting cDNA (35 ng) was PCR amplified, using the forward and reverse primers for *IGS1R*, *IGS1F*, *IGS2*, *UBC6* (Supplemental Table T1), under the following conditions: denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec and elongation at 68°C for 30 sec with 16 cycles for *UBC6* and 24 cycles for ncRNAs. Taq polymerase was from Eppendorf (Hamburg, Germany). [α -³²P]dATP (Amersham, GE Healthcare) was added to the reaction mixture (0.04 µCi/µl). Template titration for each sample was performed in order to evaluate the linear range of the

1
2
3
4 amplification. The amplified fragments were separated on a 6% acrylamide gel and
5
6 quantification was performed using ImageJ 1.42q. ncRNA bands intensity was
7
8 normalized to the *UBC6* value. Average (with standard deviations) refers to at least
9
10 three independent ratios: [mutant or transformed strain ncRNA/ *UBC6* RNA]/[wild-type
11
12 ncRNA/*UBC6* RNA]. p-values were obtained using Student's t-test.
13
14
15
16
17
18

19 **Chromatin Immunoprecipitation (ChIP)**

20
21 Exponential phase cultures (200 ml) were cross linked with 1% formaldehyde at room
22
23 temperature for 15min (for acH4K16 or total H4 immunoprecipitation) or 20 min (for
24
25 Sir2p immunoprecipitation), and then incubated with 330mM glycine for 10min, to
26
27 quench the formaldehyde reaction. Cells were then processed for ChIP as described
28
29 (26). Cells were washed with 140mM NaCl, 2.5mM KCl, 8.1mM Na₂HPO₄, 1.5mM NaCl,
30
31 1mM EDTA, 1%TritonX-100, 0.1% sodium deoxycholate, 0.1%SDS, protease inhibitors
32
33 and lysed with glass beads, by vigorous shaking for 1h at 4°C. Chromatin extracts were
34
35 recovered and subjected to sonication four times for 20 sec at an amplitude needed to
36
37 obtain an average DNA fragment size of 500 to 1000 bp. Equal amounts of chromatin
38
39 extract (350µg of Bradford quantified proteins) were treated as Input (i.e. genomic non-
40
41 immunoprecipitated DNA) or as IP (Immunoprecipitated DNA). IP samples were
42
43 incubated at 4°C overnight, at the final concentration of 140mM NaCl, with 100µg of
44
45 BSA and 2.5µg of antibodies against Sir2p, histone H4 terminal tail, or acetylated
46
47 H4K16. Chromatin antibody complexes were isolated with protein A Sepharose beads
48
49 (Amersham, GE Healthcare) for 1.5h at 4°C. Beads were then washed with lysis buffer
50
51 containing increasing amounts of NaCl, deoxycholate buffer (10mM Tris- HCl pH 8,
52
53 1mM EDTA). Immunoprecipitated chromatin was then eluted by incubation with 100µl of
54
55
56
57
58
59
60
61
62
63
64
65

50mM Tris- HCl pH 8, 10mM EDTA, 1%SDS at 65°C for 15min. All samples (IP and Input) were then incubated at 65°C overnight to reverse the crosslinking, treated with 0.5 µg/ml proteinase K and 0.25 µg/ml RNase A. The recovered DNA was resuspended in 200µl for Input samples and in 50µl for IP samples. 1µl from Input and 3µl from IP were used as template for PCR in order to obtain comparable autoradiographic signals. PCR was performed under the following conditions: denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec, and elongation at 68°C for 30 sec, with 17 cycles for IGS rDNA sequences and 27 cycles for ACTIN. α -³²P dATP was added to the reaction mixture (0.04µCi/µl). Multiplex PCR reactions were performed between: (ENH/ARS/ACT1); (E-pro/C-pro/ACT1); (5S/ACT1). The amplified fragments were separated on a 6% acrylamide gels and quantification was performed using ImageJ 1.42q.

The fold enrichment values, obtained using antibodies, were calculated as follows: $[\text{rDNA(IP)}/\text{ACT1(IP)}] / [\text{rDNA(Input)}/\text{ACT1(Input)}]$. Final values relative to acH4K16 were obtained after normalization to total H4 values. After this calculation, the isogenic wild-type *TOP1* strain values were normalized to 1, obtaining the enrichment amount shown for the different strains or conditions. The graphs show the mean and standard deviation of relative enrichments calculated from three different PCR experiments. p-values were obtained using Student's t-test.

Co-immunoprecipitations

Galactose-induced cultures of EKY2 (*SIR2*) or MHY16 (*sir2Δ*) cells expressing N-terminal FLAG-tagged Top1p were lysed with prechilled (-20°C) glass beads in 50 mM

1
2
3
4 Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 200 mM KCl, and 10% glycerol, supplemented
5
6 with complete protease inhibitors (Roche). Triton X-100 was added to a final
7
8 concentration of 1%. Aliquots were incubated with anti-FLAG agarose beads (Sigma)
9
10 and rotated end-over-end for 2 hours at 4°C. The samples were washed five times with
11
12 50 mM Tris, pH7.4, 200 mM KCl and protease inhibitors. SDS sample buffer lacking
13
14 DTT was added to each sample and the proteins were resolved by SDS-PAGE and
15
16 visualized by immunoblotting with antibodies specific for the FLAG epitope tag onTop1p
17
18 or Sir2p.
19
20
21
22
23
24

25 26 **ACKNOWLEDGMENTS**

27
28 We thank Dr. Stephen G. Aller for helpful discussions about protein structure.
29

30
31 This work was partially supported by the Istituto Pasteur-Fondazione Cenci Bolognetti
32
33 Università di Roma La Sapienza, the Epigenomics Flagship Project EpiGen, the Italian
34
35 Ministry of Education and Research, National Research Council, NIH grant CA58755
36
37 and the University of Alabama at Birmingham Comprehensive Cancer Center Core
38
39 grant P30CA013148.
40
41
42
43
44

45 46 **REFERENCES**

47
48 1. Petes, T.D. (1979). Yeast ribosomal DNA genes are located on chromosome XII.
49
50 Proc. Natl. Acad. Sci. USA. 76 :410-4.
51

52
53
54
55 2. Kobayashi, T., Nomura, M. & Horiuchi, T. (2001). Identification of DNA cis elements
56
57 essential for expansion of ribosomal DNA repeats in *Saccharomyces cerevisiae*. Mol.
58
59 Cell. Biol. 21: 136-47.
60
61
62
63
64
65

- 1
2
3
4
5
6
7 3. Kobayashi, T. & Ganley, A.R. (2005). Recombination regulation by transcription-
8 induced cohesin dissociation in rDNA repeats. *Science*. 309: 1581-4.
9
10
11
12
13
- 14 4. Nomura, M. (2001). Ribosomal RNA genes, RNA polymerases, nucleolar structures,
15 and synthesis of rRNA in the yeast *Saccharomyces cerevisiae*. Cold Spring Harb Symp
16 Quant Biol. 66: 555-65.
17
18
19
20
21
22
- 23 5. Cesarini, E., D'Alfonso, A. & Camilloni, G. (2012). H4K16 acetylation affects
24 recombination and ncRNA transcription at rDNA in *Saccharomyces cerevisiae*. *Mol.*
25 *Biol. Cell*. 23: 2770-81.
26
27
28
29
30
31
32
- 33 6. Bryk, M., Banerjee, M., Murphy, M., Knudsen, K.E., Garfinkel, D.J.& Curcio, M.J.
34 (1997). Transcriptional silencing of Ty1 elements in the RDN1 locus of yeast. *Genes*
35 *Dev*. 11: 255-69.
36
37
38
39
40
41
42
- 43 7. Smith, J.S. & Boeke, J.D. (1997). An unusual form of transcriptional silencing in yeast
44 ribosomal DNA. *Genes Dev*. 11: 241-54.
45
46
47
48
49
- 50 8. Li, C., Mueller, J.E.& Bryk, M. (2006). Sir2 represses endogenous polymerase II
51 transcription units in the ribosomal DNA nontranscribed spacer. *Mol. Biol. Cell*. 17:
52 3848-59.
53
54
55
56
57
58
59
60
61
62
63
64
65

09. Gottlieb, S. & Esposito, R.E. (1989). A new role for a yeast transcriptional silencer gene, SIR2, in regulation of recombination in ribosomal DNA. *Cell*. 56: 771-6.
10. Kaeberlein, M., McVey, M. & Guarente, L. (1999). The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev*. 13: 2570-80.
11. Robyr, D., Suka, Y., Xenarios, I., Kurdistani, S.K., Wang, A., Suka, N. & Grunstein, M. (2002). Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. *Cell*. 109: 437-46.
12. Tanny, J.C., Dowd, G.J., Huang, J., Hilz, H. & Moazed, D. (1999). An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. *Cell*. 99: 735-45.
13. Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature*. 403: 795-800.
14. Landry, J., Sutton, A., Tafrov, S.T., Heller, R.C., Stebbins, J., Pillus, L. & Sternglanz, R. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. *Proc. Natl. Acad. Sci. USA* 97: 5807-11.

- 1
2
3
4 15. Smith, J.S., Brachmann, C.B., Celic, I., Kenna, M.A., Muhammad, S., Starai, V.J. &
5
6 Avalos, J.L.,(2000). A phylogenetically conserved NAD⁺ - dependent protein
7
8 deacetylase activity in the Sir2p protein family. Proc. Natl. Acad. Sci. USA. 97: 6658-63.
9
10
11
12
13
14 16. Christman, M.F., Dietrich, F.S. & Fink, G.R. (1988). Mitotic recombination in the
15
16 rDNA of *S. cerevisiae* is suppressed by the combined action of DNA topoisomerases I
17
18 and II. Cell. 55: 413-25.
19
20
21
22
23
24 17. Fritze, C.E., Verschueren, K., Strich, R. & Easton Esposito. R. (1997). Direct
25
26 evidence for SIR2 modulation of chromatin structure in yeast rDNA. EMBO J. 16: 6495-
27
28 509.
29
30
31
32
33
34 18. Megonigal, M.D., Fertala, J. & Bjornsti, M-A. (1997). Alterations in the catalytic
35
36 activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. J. Biol.
37
38 Chem. 272: 12801-8.
39
40
41
42
43 19. Cioci, F., Vogelauer, M. & Camilloni, G. (2002). Acetylation and accessibility of
44
45 rDNA chromatin in *Saccharomyces cerevisiae* in Δ top1 and Δ sir2 mutants. J. Mol. Biol.
46
47 322: 41-52.
48
49
50
51
52
53 20. Vasiljeva, L., Kim, M., Mutschler, H., Buratowski, S. & Meinhart, A. (2008). The
54
55 Nrd1-Nab3-Sen1 termination complex interacts with the Ser5-phosphorylated RNA
56
57 polymerase II C-terminal domain. Nat. Struct. Mol. Biol. 15: 795-804.
58
59
60
61
62
63
64
65

- 1
2
3
4 21. Cesarini, E., Mariotti, F.R., Cioci, F. & Camilloni, G. (2010). RNA polymerase I
5 transcription silences noncoding RNAs at the ribosomal DNA locus in *Saccharomyces*
6 *cerevisiae*. *Eukaryot. Cell.* 9: 325-35.
7
8
9
10
11
12
13
14 22. Wright, C.M., van der Merwe, M., DeBrot, A.H. & Bjornsti, M-A. (2015) DNA
15 topoisomerase I domain interactions impact enzyme activity and sensitivity to
16 camptothecin. *J. Biol. Chem.* 290:12068-78.
17
18
19
20
21
22
23
24 23. Teste, M.A., Duquenne, M., François, J.M. & Parrou, J.L. (2009). Validation of
25 reference genes for quantitative expression analysis by real-time RT-PCR in
26 *Saccharomyces cerevisiae*. *BMC Mol. Biol.* 10: 99.
27
28
29
30
31
32
33
34 24. Eng, W.K., Pandit, S.D. & Sternglanz, R. (1989). Mapping of the active site tyrosine
35 of eukaryotic DNA topoisomerase I. *J. Biol. Chem.* 264: 13373-6.
36
37
38
39
40
41 25. Lynn, R.M., Bjornsti, M-A., Caron, P.R. & Wang, J.C. (1989) Peptide sequencing
42 and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of
43 *Saccharomyces cerevisiae* DNA topoisomerase I. *Proc. Natl. Acad. Sci. U S A.*, 86:
44 3559-63.
45
46
47
48
49
50 26. Hann, C.L., Carlberg, A.L. & Bjornsti, M-A. (1998). Intragenic suppressors of mutant
51 DNA topoisomerase I-induced lethality diminish enzyme binding of DNA. *J. Biol. Chem.*
52 273:31519-27.
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 27. Koster, D.A., Palle, K., Bot, E.S., Bjornsti, M-A. & Dekker NH. (2007). Antitumour
5 drugs impede DNA uncoiling by topoisomerase I. *Nature* 448: 213-7.
6
7
8
9
10
11 28. Pommier, Y., Leo, E., Zhang, H. & Marchand, C. (2010). DNA topoisomerases and
12 their poisoning by anticancer and antibacterial drugs. *Chemistry & Biology* 17: 421-33.
13
14
15
16
17
18 29. Chen, S.H., Chan, N.L. & Hsieh, T.S. (2013). New mechanistic and functional
19 insights into DNA topoisomerases. *Annu. Rev. Biochem.* 82: 139-70.
20
21
22
23
24
25 30. Vogelauer, M. & Camilloni, G. (1999). Site-specific in vivo cleavages by DNA
26 topoisomerase I in the regulatory regions of the 35 S rRNA in *Saccharomyces*
27 *cerevisiae* are transcription independent. *J. Mol. Biol.* 293: 19-28.
28
29
30
31
32
33 31. D'Arpa, P., Machlin, P.S., Ratrie, H. 3rd, Rothfield, N.F., Cleveland, D.W. &
34 Earnshaw, W.C. (1988). cDNA cloning of human DNA topoisomerase I: catalytic activity
35 of a 67.7-kDa carboxyl-terminal fragment. *Proc. Natl. Acad. Sci. USA* 85: 2543-7.
36
37
38
39
40
41
42
43
44 32. Stewart, L., Ireton, G.C. & Champoux, J.J. (1996). The domain organization of
45 human topoisomerase I. *J. Biol. Chem.* 271: 7602-8.
46
47
48
49
50
51
52 33. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J. & Hol, W.G.J. (1998). Crystal
53 structures of human topoisomerase I in covalent and noncovalent complexes with DNA.
54 *Science* 279: 1504-13.
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 34. Woo, M.H., Losasso, C., Guo, H., Pattarello, L., Benedetti, P. & Bjornsti, M-A.
5
6 (2003). Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and
7
8 induces cell lethality. *Proc. Natl. Acad. Sci.USA.* 100: 13767-72.
9
10
11
12
13
14 35. Palle, K., Pattarello, L., van der Merwe, M., Losasso, C., Benedetti, P. & Bjornsti, M-
15
16 A. (2008). Disulfide cross-links reveal conserved features of DNA topoisomerase I
17
18 architecture and a role for the N terminus in clamp closure. *J. Biol. Chem.* 283: 2776-75.
19
20
21
22
23 36. Alsner, J., Svejstrup, J.Q., Kjeldsen, E., Sørensen, B.S. & Westergaard, O. (1992).
24
25 Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable
26
27 for catalytic activity but essential for in vivo function. *J. Biol. Chem.* 267: 12408-11.
28
29
30
31
32
33 37. Huang, J. & Moazed, D. (2003). Association of the RENT complex with
34
35 nontranscribed and coding regions of rDNA and a regional requirement for the
36
37 replication fork block protein Fob1 in rDNA silencing. *Genes Dev.* 17: 2162-76.
38
39
40
41
42
43 38. Lotito, L., Russo, A., Chillemi, G., Bueno, S., Cavalieri, D. & Capranico G.(2008).
44
45 Global transcription regulation by DNA topoisomerase I in exponentially growing
46
47 *Saccharomyces cerevisiae* cells: activation of telomere-proximal genes by TOP1
48
49 deletion. *J. Mol. Biol.* 377:311-22.
50
51
52
53
54
55 39. Girstun, A., Kowalska-Loth, B., Czuby, A., Kloczek, M. & Staroń, K. (2008).
56
57 Fragment responsible for translocation in the N-terminal domain of human
58
59 topoisomerase I. *Biochem. Biophys. Res. Commun.* 366:250-7.
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9 40. Smith, J.S., Caputo, E. & Boeke, J.D. (1999). A genetic screen for ribosomal DNA
10 silencing defects identifies multiple DNA replication and chromatin-modulating factors.
11 Mol. Cell. Biol. 19: 3184-97.
12
13
14
15

16
17
18
19 41. Blander, G. & Guarente, L. (2004). The Sir2 family of protein deacetylases. Annu.
20 Rev. Biochem. 73: 417-35.
21
22
23

24
25
26 42. Colley, W.C., van der Merwe, M., Vance, J.R., Burgin, A.B. Jr & Bjornsti, M-A.
27 (2004). Substitution of conserved residues within the active site alters the cleavage
28 religation equilibrium of DNA topoisomerase I. J. Biol. Chem. 279: 54069-78.
29
30
31
32

33
34
35
36 43. Kretzschmar, M., Meisterernst, M. & Roeder, R.G. (1993). Identification of human
37 DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA
38 polymerase II. Proc. Natl. Acad. Sci. USA. 90: 11508-12.
39
40
41
42

43
44
45 44. Merino, A., Madden, K.R., Lane, W.S., Champoux, J.J. & Reinberg, D. (1993). DNA
46 topoisomerase I is involved in both repression and activation of transcription. Nature.
47 365: 227-32.
48
49
50
51

52
53
54
55 45. Edwards, T.K., Saleem, A., Shaman, J.A., Dennis, T., Gerigk, C., Oliveros, E. &
56 Gartenberg, M.R. (2000). Role for nucleolin/Nsr1 in the cellular localization of
57 topoisomerase I. J. Biol. Chem. 275: 36181-8.
58
59
60
61

- 1
2
3
4
5
6
7 46. Kauh, E.A. & Bjornsti, M-A. (1995) SCT1 mutants suppress the camptothecin
8
9 sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc. Natl. Acad.
10
11 Sci. U S A., 92, 6299-303.
12
13
14
15
16 47. Sherman, F., Fink, G.R. & Lawrence, C. (1983). Methods in Yeast Genetics, Cold
17
18 Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
19
20
21
22
23 48. Verdone, L., Camilloni, G., Mauro, E.D., & Caserta, M. (1996). Chromatin
24
25 remodeling during *Saccharomyces cerevisiae* ADH2 gene activation. Mol. Cell. Biol. 16,
26
27 1978–1988.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Legends

Figure 1. Schematic map of the ribosomal genes in *S. cerevisiae*. Horizontal grey arrows represent the 35S RNA pol I and 5 S RNA pol III transcripts. Black arrows represent the ncRNA Pol II transcripts, intergenic spacer IGS1F and IGS1R from E-pro, and IGS2 from C-pro. Filled boxes indicate 35S and 5S coding units. Ellipses refer to positioned nucleosomes. The boxed areas in the lower part of the figure delineate the relative position of DNA sequences used for ChIP experiments, while the arrows indicate the orientation of oligonucleotides used for RT-PCR or primer extension.

Figure 2. *top1Δ* induces increased H4K16 acetylation and the loss of E-pro promoter silencing within the IGS of rDNA.

A: ChIP analysis of H4K16 acetylation at rDNA. Extracts from crosslinked wild-type and *top1Δ* cells were immunoprecipitated with an anti -H4K16 or anti -H4 antibody. The DNA recovered from the immunoprecipitated chromatin was amplified to analyze 5 rDNA regions specified in Figure 1. H4K16 acetylation data were normalized to total H4 and then to values obtained with wild-type cells (wild-type=1, dotted line). Values with standard deviations from three independent experiments are reported. * p <0.05 and ** p <0.01.

B: RT-PCR analysis of ncRNA expression. RNA from wild-type and *top1Δ* strains was analyzed. The levels of ncRNA transcripts were normalized to *UBC6* mRNA and then to values obtained from wild-type cells (wild-type=1, dotted line). In the histogram, values with standard deviations from three independent experiments are reported. ** p <0,01.

Figure 3. Enzymatic activity of Top1 is dispensable for H4K16 acetylation and ncRNA silencing at IGS.

A: H4K16 acetylation at Enh, E-pro, 5S, ARS, C-pro (regions 1,2,3,4,5 in Fig. 1) were detected by ChIP as in Fig 2. Data from *top1Δ* cells are shown as black bars, from *top1Δ* cells expressing *yTOP1* as grey bars, and from *top1Δ* cells expressing *ytop1Y727F* (a catalytically inactive mutant of *yTOP1*) as white bars. Normalized data obtained from wild-type *TOP1* cells = 1 (dotted line). Values with standard deviations from three independent experiments are reported. * $p < 0.05$ ** $p < 0.01$.

B: IGS1R ncRNA expression assessed by RT-PCR in the same strains as in A, and as described in the legend to Fig. 2. Normalized data from wild-type *TOP1* cells = 1 (dotted line). Values with standard deviations from three independent experiments are reported.

* $p < 0.05$ ** $p < 0.01$

Figure 4. AchH4K16 and silencing of IGS1R are similar in *top1Δ* mutants and *top1Δ* cells expressing human *TOP1*.

A: ChIP analysis of H4K16 acetylation, as in Fig. 2 legend. Data from *top1Δ* cells in black bars, from *top1Δ* cells expressing *yTOP1* from the *GAL1* promoter in grey bars, and from *top1Δ* cells expressing *hTOP1* from the *GAL1* promoter in white bars.

Normalized data from wild-type *TOP1* cells =1, dotted line. Values with standard deviations from three independent experiments are reported. * $p < 0.05$ ** $p < 0.01$.

B: IGS1R ncRNA levels produced by *top1Δ* yeast cells expressing yeast or human *TOP1* (as in A) were assessed by RT-PCR as described in Fig. 2 legend. Normalized wild-type *TOP1* strain data =1, dotted line, Values with standard deviations from three independent experiments are reported. * $p < 0.05$ ** $p < 0.01$.

Figure 5. Sc210h*top1* complements *top1Δ*-induced alterations in H4K16 acetylation and IGS1R ncRNA production.

A: ChIP analysis of acetylated H4K16, as in Fig. 2, was performed in wild-type *TOP1* cells (dotted line), *top1Δ* cells (black bars), *top1Δ* cells expressing y*TOP1* (grey bars), and *top1Δ* expressing the yeast/human chimera Sc210h*top1* (white bars). Values with standard deviations from three independent experiments are reported. *P<0.05, **P<0.01.

B: IGS1R ncRNA transcription detected by RT-PCR in the same strains as in A, as described in Fig. 2 legend. All data were normalized to *UBC6* expression, then to data obtained with wild-type *TOP1* cells (dotted line); values with standard deviations from three independent experiments are reported. * p <0.05, ** p <0.01

Figure 6. Sir2p enrichment at rDNA is influenced by the yeast N-terminal domain of Top1p, but not Top1p enzymatic activity.

ChIP assays of acetylated H4K16, performed in extracts of *top1Δ* cells (black bars), or *top1Δ* cells expressing plasmid-encoded y*TOP1* (dark grey bars), y*top1Y727F* (light grey bars), h*TOP1* (dot bars) or Sc210h*top1* (white bars), subjected to immunoprecipitation with an anti-Sir2p antibody. DNA recovered from chromatin was PCR amplified using oligonucleotides annealing to Enhancer (region 1) or C-pro (region 5) sequences as diagrammed in Fig. 1. All values are normalized to wild-type *TOP1* cells (dotted line). Values with standard deviations from three independent experiments are reported. *p<0.05 and ** p<0.01.

Figure 7. IGS1R ncRNA transcription in yeast cells expressing chimera *TOP1* genes *Sc201hTOP1*, *Sc192hTOP1*, *h138ScTOP1*, *h120ScTOP1*.

A: Alignment of amino acid residues spanning the chimera junctions of yeast (pink residues) and human (black residues) Top1p, as described in (22). Color coded numbers refer to residue number, while numbered allele designations indicate the first residue of the C-terminal yeast (pink) or human (black) Top1p sequences contained in the chimeric enzymes. In ScΔ201h, sequences encoding 8 residues of yeast Top1p, just N-terminal to the chimera junction, were deleted during plasmid construction (indicated by a yellow line). ScTopo70p lacks the first 102 residues and corresponds to human Topo70 constructs that lack the first 174 amino acid residues of human Top1p (35). Stretches of 6 or more acidic residues shared by ScTop1, ScTopo70, ScΔ201h and Sc210h are highlighted in yellow, while shorted patches of Glu residues in the all constructs are in blue.

B: As in Fig. 2 legend, ncRNA expression in *top1Δ* strains expressing the indicated chimera or Top1 protein, was detected by RT-PCR, and normalized to *UBC6* and data from wild-type *TOP1* cells (dotted line). Values with standard deviations from three independent experiments are reported. *p<0,05; **p>0,01.

Figure 8. Yeast Top1p, but not human Top1p, physically interacts with Sir2p. Co-immunoprecipitation analyses were performed with extracts of *top1Δ*, *SIR2* (left panel) or *top1Δ*, *sir2Δ* (right panel) cells expressing the indicated yeast, human and chimera Top1 proteins. Lysates were incubated with beads linked to anti-FLAG antibodies. The resulting immunoprecipitates, and input lysate samples were then subjected to

immunoblot analysis with antibodies specific for the FLAG-tagged Top1 proteins or Sir2p. GAPDH served as loading control for lysates.

Figure 1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)





Figure 3
[Click here to download high resolution image](#)





Figure 4
[Click here to download high resolution image](#)





Figure 5
[Click here to download high resolution image](#)





Figure 6
[Click here to download high resolution image](#)




Figure 7
[Click here to download high resolution image](#)

A



B





Figure 8
[Click here to download high resolution image](#)



Supplementary Material (Not to be Published)

[Click here to download Supplementary Material \(Not to be Published\): JMB_2016 Supplemental Figures.pdf](#)

Supplementary Material (Not to be Published)

[Click here to download Supplementary Material \(Not to be Published\): JMB_2016 Supplemental Table 1.pdf](#)